CERo Therapeutics Holdings, Inc.
OTC: CERO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher Ehrlich
- Employees
- 8
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $9.8K
- Website
- https://www.cero.bio
Loading CERO…
Loading profile data…Frequently asked questions about CERO
What does CERo Therapeutics Holdings, Inc. (CERO) do?
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. Th...
Where does CERO trade?
CERo Therapeutics Holdings, Inc. (CERO) trades on the Other OTC.
What sector is CERO in?
CERo Therapeutics Holdings, Inc. (CERO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CERo Therapeutics Holdings, Inc.?
Christopher Ehrlich is the chief executive officer of CERo Therapeutics Holdings, Inc. (CERO).
Where is CERo Therapeutics Holdings, Inc. headquartered?
CERo Therapeutics Holdings, Inc. is headquartered in United States.
Does CERO pay a dividend?
CERo Therapeutics Holdings, Inc. (CERO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CERO go public?
CERo Therapeutics Holdings, Inc. (CERO) completed its initial public offering in 2021.